AUS
NZ
UK
CA
USA
IND
Healt
Race Oncology Advances in ASX All Ords Healthcare
March 19, 2026 01:56 PM AEDT| By SamRace Oncology (ASX:RAC) highlights biotechnology sector activity within ASX All Ordinaries, focusing on clinical development and healthcare innovation.
Is All Ordinaries Neurizon Expanding Its Share Base?
March 19, 2026 12:22 PM AEDT| By SamNeurizon Therapeutics seeks ASX quotation for new shares, reflecting capital structure updates and healthcare sector activity within the All Ordinaries market framework.
Adherium Share Move Sparks ASX Market Attention
March 19, 2026 11:35 AM AEDT| By SamAdherium’s share quotation expansion highlights liquidity changes, strategic capital alignment, and the growing importance of digital health within Australia’s evolving market environment.
Orthocell Advances Global Reach with Remplir Success
March 19, 2026 06:42 AM AEDT| By SamOrthocell’s Remplir device demonstrates real-world effectiveness in complex surgical cases, supporting global expansion and strengthening its position across advanced medical and defence healthcare markets.
4DMedical Advances Share Quotation Move Amid ASX 200 Focus
March 18, 2026 05:20 PM AEDT| By Sam4DMedical advances its share quotation process, aligning with ASX requirements while reflecting ongoing capital structure updates within the healthcare technology segment.
ASX 300 Nanosonics Unveils New Share Incentive Move
March 18, 2026 03:54 PM AEDT| By SamNanosonics seeks ASX quotation for employee incentive shares, reflecting equity structure updates and governance activity within the ASX 300 healthcare technology sector.
Healthcare Sector Activity Across the ASX Market
March 18, 2026 02:10 PM AEDT| By SamCann Group progresses ASX share quotation plans, highlighting capital market activity within the healthcare sector and its role across the All Ordinaries index.
Can Sofdra Drive a Turnaround for ASX Healthcare Stock?
March 18, 2026 12:42 PM AEDT| By SamBotanix Pharmaceuticals faces a defining phase as Sofdra adoption, cost control, and platform strength determine whether its commercial strategy can stabilise momentum in a competitive healthcare landscape.
Biotech Sector Activity Across Australian Market
March 18, 2026 12:33 PM AEDT| By SamOrthocell’s nerve repair technology highlights biotechnology innovation within global healthcare, supporting surgical procedures and advancing regenerative medicine applications across clinical environments.
Which All Ordinaries Healthcare Stock Gains on Trial News?
March 18, 2026 12:04 PM AEDT| By SamHealthcare stock activity within the All Ordinaries highlights clinical progress and sector participation, reflecting ongoing developments in biotechnology and research-driven industries.
Recce Webinar to Spotlight Phase 3 and Pipeline Progress
March 17, 2026 03:52 PM AEDT| By SamRecce Pharmaceuticals Ltd (ASX:RCE) will host a webinar covering Phase 3 trials, anti-infective pipeline updates, and a US Army research collaboration for burn wound treatment.
Is All Ordinaries Biotech Innovation Driving Precision Medicine?
March 17, 2026 01:49 PM AEDT| By SamTetraTherix advances precision medicine initiatives through biomaterial technology and collaborative biotechnology research, highlighting healthcare innovation within the broader All Ordinaries biotech landscape.
Is ASX All Ords Focus Turning to Prescient Therapeutics?
March 17, 2026 01:37 PM AEDT| By SamPrescient Therapeutics operates within the biotechnology sector conducting oncology research and clinical trial programs focused on developing cancer treatment technologies.
ASX 100 Healthcare Leader Sonic Healthcare in Focus
March 17, 2026 01:27 PM AEDT| By SamSonic Healthcare operates a global network of pathology laboratories and diagnostic imaging centres that support medical testing services within healthcare systems and the broader ASX healthcare sector.
Is ASX 300 Focus Turning to Clarity Pharma Activity?
March 17, 2026 12:13 PM AEDT| By SamClarity Pharmaceuticals operates in the biotechnology sector developing radiopharmaceutical technologies focused on cancer diagnostics and targeted oncology research.
Tetramatrix Push Expands Global Reach for (ASX:TTX)
March 16, 2026 07:21 PM AEDT| By SamTetratherix expands its Tetramatrix platform through a precision medicine franchise and US collaboration, advancing nasal drug delivery technology while strengthening its presence in regenerative medicine and biotechnology innovation.
Cochlear (ASX:COH) Gains Attention Across ASX 50 on Implant Tech
March 16, 2026 07:12 PM AEDT| By SamCochlear Limited activity within the ASX 50 highlights implantable hearing technology, global healthcare distribution networks, and ongoing advancements in medical device innovation.
Clarity Pharma (ASX:CU6) AMPLIFY Trial Consent Completed, ASX 300 Watch
March 16, 2026 06:00 PM AEDT| By SamClarity Pharmaceuticals activity within the ASX 300 reflects progress in radiopharmaceutical research as a prostate cancer imaging trial advances through clinical development stages.
AI Autism Diagnostic Study Network Expands Across U.S.
March 16, 2026 03:42 PM AEDT| By SamA new autism diagnostic study network in the United States advances smartphone-based AI healthcare tools, marking an important milestone in digital diagnostics and the future of technology-driven clinical assessment.
Healthcare Stocks in Focus Amid Global Market Uncertainty
March 13, 2026 09:43 PM AEDT| By SamAustralian healthcare stocks remain active despite global uncertainty as biotech companies progress drug trials, regulatory reviews, and partnerships, keeping the sector in focus across the broader Australian equities market.
Advertise your brand on Kalkine Media